VANI

4 - Vivani Medical, Inc. (0001266806) (Issuer)

8-K - Vivani Medical, Inc. (0001266806) (Filer)

10-K - Vivani Medical, Inc. (0001266806) (Filer)

Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026. Single preclinical administration of semaglutide implant configuration demonstrates continued semaglutide exposure and >20% sham-adjusted weight loss for a full year. Solid cash position from multiple recent financings will support operations into mid-2027 and enable the projected completion of key milestones including the Phase 1 study of NPM-139. ALAMEDA, Calif., March 26

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology  Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. ("Cortigent"), its wholly-owned subsidiary developing brain implant de

4 - Vivani Medical, Inc. (0001266806) (Issuer)

8-K - Vivani Medical, Inc. (0001266806) (Filer)

ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. Gross proceeds from the two transactions were approximately $4.5 million, before deducting fees and offering expens

424B5 - Vivani Medical, Inc. (0001266806) (Filer)

ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. The registered offering and the private placement were priced "at-the-market" under the rules and regulations of The Nasdaq Stock Market LLC

Cortigent is a leading developer of brain interface devices based on precision neurostimulation technology  The company's new Orion cortical stimulation system for visual perception, designed to treat most common forms of blindness, successfully completed a six-year Early Feasibility Study Cortigent is also developing a new medical device aimed at improving the recovery of arm and hand motion in patients suffering from paralysis due to stroke ALAMEDA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that its wholly-own

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

10-Q - Vivani Medical, Inc. (0001266806) (Filer)

8-K - Vivani Medical, Inc. (0001266806) (Filer)

Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 results and regulatory feedback 3Q 2025 private placement, together with October financings, generated approximately $25.7M in cash and cash commitments to support accelerated development of NPM-139 while securing financial position into 2027 ALAMEDA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, ultra long-acting drug implants, today reporte

ALAMEDA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 6,000,000 shares of its common stock at an offering price of $1.62 per share and a concurrent private placement of 3,703,703 shares of its common stock at an offering price of $1.62 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. Gross proceeds from the two transactions were approximately $15.7 million, before deducting fees and offering expen

4 - Vivani Medical, Inc. (0001266806) (Issuer)

8-K - Vivani Medical, Inc. (0001266806) (Filer)